Enable Injections
- Industry
- Medical Devices & Instruments
- Founded Year
- 2010
- Headquarters
- Cincinnati, Ohio, USA
- Employee Count
- 200
Key People
- Michael D. Hooven - Founder and CEO
- Tim Flaherty - Chief Financial Officer
- David Kroeger - Chief Operating Officer
- Mary Beth Popp - Vice President of Corporate Communications
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with a strong background in medical technology and business development.
The leadership team's collective experience in MedTech and business development enhances the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: The enFuse device addresses a significant need for patient-friendly, large-volume drug delivery solutions.
The enFuse device offers a solution for patients requiring large-volume subcutaneous drug delivery, enhancing comfort and adherence, which is increasingly important in chronic disease management.
- Competition
-
Aspect: Somewhat crowded
Summary: The wearable injector market has several established players, but enFuse offers unique features.
While the market includes competitors like Insulet Corporation and Ypsomed, enFuse's unique design and strategic partnerships provide a competitive edge.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of enFuse involves manageable technical challenges with established solutions.
The technical aspects of developing wearable injectors are well-understood, and the company's experience reduces the likelihood of unforeseen challenges.
- Patent
-
Aspect: Strong
Summary: Enable Injections holds several patents protecting its enFuse technology.
A robust patent portfolio safeguards the company's innovations, deterring competitors and supporting market exclusivity.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from strategic investors.
Investments from major pharmaceutical companies and venture capital firms provide the necessary resources for scaling operations and market penetration.
- Regulatory
-
Aspect: 510k/PMA
Summary: enFuse has received regulatory approvals, including CE Mark in Europe.
Achieving regulatory approvals demonstrates compliance with safety and efficacy standards, facilitating market entry and adoption.
Opportunity Rollup
- Odds of Success
- 3.5
- Peak Market Share
- 4.4
- Segment CAGR
- 13%
- Market Segment
- Wearable Injectors
- Market Sub Segment
- On-Body Injectors
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.66 |
| 3 | 1.54 |
| 4 | 3.08 |
| 5 | 4.40 |
Key Takeaway
Enable Injections' enFuse device is well-positioned to capitalize on the growing demand for patient-friendly, home-based drug delivery solutions, supported by strong leadership and strategic partnerships.